What Does Alnylam Pharmaceuticals ($ALNY) Do? – Stock Outlook, Earnings, Market Cap, Related Stocks, and Headquarters Overview
Alnylam Pharmaceuticals (ALNY) is a leading biotech company at the forefront of RNA interference (RNAi)-based therapeutics for rare diseases, distinguished by multiple approved products and an expanding pipeline. Summary of ALNY stock, outlook, earnings, and related stocks.
🏢 What kind of company is Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals (ALNY) is a biotech company founded in 2002 in Cambridge, Massachusetts, that has established a global leadership position in RNA interference (RNAi) therapeutics. It is a leading group in the RNAi therapeutics field, operating multiple approved products and a broad clinical pipeline with a focus on rare genetic diseases.
The company's core business is the development and commercialization of novel drugs leveraging RNA interference technology. It holds an RNAi therapeutics portfolio spanning rare genetic diseases, cardiovascular, central nervous system, and hepatic conditions, and operates a business model that combines proprietary commercialization with global partnerships.
💰 How does Alnylam Pharmaceuticals make money?
| Business Segment | Revenue Mix | Description |
|---|---|---|
| RNAi Therapeutics Sales | Core | Commercialization of approved products |
| Royalty & Collaboration Revenue | Key Growth Driver | Royalties from global partnerships |
| Research Collaboration | Diversification Driver | Co-development revenue with pharmaceutical companies |
| Other & Services | Supplementary Business | Other collaboration revenue |
Commercial sales of approved RNAi therapeutics form the core of growth, while co-development and royalty arrangements with global pharmaceutical companies serve as diversifying revenue drivers. New pipeline approvals, label expansions, and the addition of launch countries are the key variables shaping revenue flows. The revenue trajectory of core assets, alongside progress in the clinical-stage pipeline, drives the company's business value dynamics.
📐 Alnylam Pharmaceuticals Market Cap and Company Scale
Market capitalization stands at $38.3B, with employee headcount of 2,500명.
As a leading RNAi therapeutics specialist ranked among the top global biotech groups by market cap, Alnylam is commonly benchmarked alongside peer biotech companies such as REGN, VRTX, and BMRN. Through its business model combining proprietary commercialization with global partnerships, revenue growth visibility is gradually expanding, while clinical data and regulatory approval outcomes drive the company's business value flows.
📈 Alnylam Pharmaceuticals Outlook and Stock Price Trends
Revenue growth from core RNAi therapeutics and the expansion of new pipeline approvals represent the medium- to long-term growth drivers. Clinical data readouts in cardiovascular and central nervous system indications, label expansions, and broader global launches are operating as margin expansion levers. In the short term, clinical trial results, regulatory approval timelines, and the burden of commercialization and R&D investments are sources of volatility, while changes in global partnership collaborations and currency movements should also be monitored as near-term variables.
- RNAi therapeutics revenue growth
- Pipeline label expansion
- Global launch country expansion
⚔️ Alnylam Pharmaceuticals Core Competitive Strengths and Risks
A leadership position in RNAi therapeutics and a broad pipeline are strengths, while clinical outcome volatility and R&D cost burden are the core risks.
💪 Core Competitive Strengths
⚠️ Core Risks
🔄 Alnylam Pharmaceuticals Competitors and Related (Beneficiary) Stocks
As direct global biotech competitors, Alnylam is commonly benchmarked against large-cap biotech peers such as REGN, VRTX, and BMRN, as well as adjacent RNA therapeutics groups. Related names include large-cap global pharmaceutical groups such as PFE, NVS, and SNNY, which are grouped with Alnylam from the perspective of RNAi therapeutics co-development and partnership relationships.
| 종목 | 회사명 | 가격 | 등락 | 시총 | PER | PBR | ROE | 배당률 |
|---|---|---|---|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals Inc | $696.28 | +0.2% | $73.0B | 17.0 | 2.3 | 14.55% | 0.56% |
| VRTX | Vertex Pharmaceuticals Inc | $483.33 | -1.4% | $122.7B | 28.6 | 6.3 | 24.2% | - |
 BMRN | Biomarin Pharmaceutical Inc | $61.37 | -1.1% | $11.9B | 44.8 | 1.9 | 4.48% | - |
| 종목 | 회사명 | 가격 | 등락 | 시총 | PER | PBR | ROE | 배당률 |
|---|---|---|---|---|---|---|---|---|
| PFE | Pfizer Inc | $25.15 | -0.4% | $143.3B | 19.3 | 1.6 | 8.29% | 6.85% |
| NVS | Novartis AG ADR | $158.83 | -0.6% | $290.7B | 24.0 | 7.0 | 30.56% | 2.8% |
| SNY | Sanofi ADR | $44.85 | -1.5% | $107.8B | 18.8 | 1.3 | 6.76% | 5.44% |
✅ Alnylam Pharmaceuticals Investor Checklist
Key checkpoints to review when considering an investment in Alnylam Pharmaceuticals. Core RNAi therapeutics revenue growth, new pipeline clinical results, global partnership royalty flows, and R&D investment burden are the key variables to monitor.
| Checkpoint | What to Verify | Current Status |
|---|---|---|
| Core Revenue | Sales trends of approved RNAi therapeutics | Expanding trend |
| Clinical Data | Key pipeline clinical results | Monitoring required |
| Launch Country Expansion | Global launch country growth | Increasing trend |
| R&D Investment | Pipeline investment vs. revenue growth | Improving trend |
Business value flows may experience short-term volatility depending on clinical data and approval outcomes. R&D cost burdens tied to active pipeline expansion, changes in global partnership collaborations, and entry of competing new therapeutics may also serve as near-term volatility factors.
Alnylam is a core biotech name combining a leadership position in RNAi therapeutics with a broad pipeline. Given clinical volatility, dollar-cost averaging and a long-term perspective are recommended.
이 글은 2026년 5월 21일 기준 정보입니다.